What is Precisis?
Founded in 2004, Precisis AG operates at the intersection of advanced engineering and clinical neurology. The company is primarily recognized for its EASEE (Epicranial Application of Stimulation Electrodes for the treatment of Epilepsy) system, which represents a paradigm shift in how clinicians approach refractory epilepsy. Unlike traditional invasive procedures, the EASEE technology focuses on individualized, precise neurostimulation, reflecting the company's commitment to ethical, patient-centric medical progress.
The organization maintains a robust collaborative framework, working alongside industry leaders to refine its technical architecture. By prioritizing the development of reliable, high-precision hardware, Precisis AG has established itself as a critical player in the neuro-technology sector, consistently pushing the boundaries of what is possible in the treatment of chronic neurological conditions.
How much funding has Precisis raised?
Precisis has raised a total of $23.2M across 1 funding round:
Other Financing Round
$23.2M
Other Financing Round (2021): $23.2M with participation from Cochlear
Key Investors in Precisis
Cochlear
A global leader in implantable hearing solutions, Cochlear specializes in the design and manufacture of advanced medical devices that restore sensory function, bringing significant expertise in neuro-technology and clinical device commercialization.
What's next for Precisis?
Looking ahead, the strategic deployment of the $23.2M will likely focus on scaling clinical trials and expanding the commercial reach of the EASEE system. As the company transitions into a more mature enterprise-level phase, the focus will shift toward long-term efficacy studies and the integration of its neurostimulation devices into standard clinical workflows. The backing from key industry partners provides not only the necessary financial runway but also the technical expertise required to navigate the complex regulatory environments of the global medical device market. Investors and stakeholders alike are monitoring the company's progress as it moves toward broader market adoption and potential expansion into additional indications for brain stimulation therapy.
See full Precisis company page
